Skip to main content
رجوع
ASCLF logo

Ascletis Pharma Inc.

جودة البيانات: 100%
ذروة بيع
ASCLF
OTC Healthcare Biotechnology
KWD 1.81
KWD 0.00 (0.00%)
القيمة السوقية: 1.91B
نطاق اليوم
KWD 1.81 KWD 1.90
نطاق 52 أسبوعًا
KWD 0.62 KWD 2.29
حجم التداول
9,000
متوسط 50 يوم / 200 يوم
KWD 1.91 / KWD 1.58
الإغلاق السابق
KWD 1.81

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -6.4 0.4
P/B 1.0 2.9
ROE % -14.0 3.7
Net Margin % -23455.7 3.9
Rev Growth 5Y % -56.2 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 -KWD 0.369
-KWD 0.369 – -KWD 0.369
39 M 1
FY2026 KWD 0.898
KWD 0.898 – KWD 0.898
1.3 B 1

النقاط الرئيسية

Revenue declined -56.24% annually over 5 years
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -343.73M
Revenue growth is decelerating — 1Y growth trails 5Y average by 41.49%
Capital intensive — 167.42% of revenue goes to capex

النمو

Revenue Growth (5Y)
-56.24%
Revenue (1Y)-97.73%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-13.97%
ROIC-11.23%
Net Margin-23455.65%
Op. Margin-23025.64%

الأمان

Debt / Equity
0.00
Current Ratio12.88
Interest Coverage0.00

التقييم

P/E Ratio
-6.35
P/B Ratio0.97
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -97.73% Revenue Growth (3Y) -84.60%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -56.24% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.28M Net Income (TTM) -300.94M
ROE -13.97% ROA -14.16%
Gross Margin 57.29% Operating Margin -23025.64%
Net Margin -23455.65% Free Cash Flow (TTM) -343.73M
ROIC -11.23% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 12.88
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -6.35 P/B Ratio 0.97
P/S Ratio 1488.83 PEG Ratio -0.04
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.91B Enterprise Value 1.05B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.28M 56.60M 54.09M 76.88M 35.00M
Net Income -300.94M -144.72M -314.84M -199.02M -209.24M
EPS (Diluted) -0.30 -0.13 -0.29 -0.18 -0.20
Gross Profit 735,000.0 25.99M -24.69M 39.17M -23.50M
Operating Income -295.42M -300.21M -343.98M -224.97M -217.11M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 2.12B 2.49B 2.66B 2.83B 3.07B
Total Liabilities 158.41M 148.94M 117.16M 100.89M 85.42M
Shareholders' Equity 1.97B 2.34B 2.54B 2.73B 2.98B
Total Debt 7.63M 8.42M 4.24M 2.75M 1.59M
Cash & Equivalents 865.73M 330.12M 2.47B 2.50B 2.71B
Current Assets 1.97B 2.33B 2.54B 2.63B 2.83B
Current Liabilities 153.05M 140.68M 108.19M 90.97M 73.77M